Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Monday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

Several other equities research analysts also recently weighed in on HUMA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 15th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. Benchmark decreased their target price on Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, BTIG Research reiterated a “buy” rating and set a $6.00 price target on shares of Humacyte in a report on Friday, November 21st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Humacyte Stock Performance

Shares of Humacyte stock opened at $1.09 on Monday. Humacyte has a 12 month low of $1.04 and a 12 month high of $5.66. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The firm has a market cap of $203.19 million, a P/E ratio of -4.72 and a beta of 1.90. The stock’s fifty day moving average price is $1.36 and its 200-day moving average price is $1.78.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.92 million. On average, equities research analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Several large investors have recently modified their holdings of HUMA. Lazari Capital Management Inc. acquired a new stake in Humacyte during the 2nd quarter worth approximately $27,000. Prudential Financial Inc. purchased a new stake in shares of Humacyte during the second quarter worth $28,000. Financial Advisors Network Inc. acquired a new stake in shares of Humacyte in the second quarter valued at $28,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Humacyte in the second quarter valued at $30,000. Finally, Valeo Financial Advisors LLC purchased a new position in Humacyte in the second quarter valued at $32,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.